OBJECTIVE: To observe the therapeutic effects of midnight-noon ebb-flow method of selecting acupoints (MNEFMSA) for acute ischemic cerebrovascular diseases (AICD) and its influence on hemorrheology and on the levels of interleukin-6 (IL-6), thromboxane B2 (TXB2) and 6-keto-prostaglandin F1alpha (6-keto-PGF1alpha). METHODS: The 90 cases were randomly divided into 3 groups, each consisting of 30 cases. The drug group was treated mainly by routine medication; in addition to medication, the affected-channel group was treated by acupuncture at points along the course of the affected channel, and the MNEFMSA group was treated by MNEFMSA. RESULTS: The total effective rate of MNEFMSA group, affected-channel group and drug group was 96.67%, 90% and 73.33% respectively. The total effective rate of MNEFMSA group was obviously superior to that of the drug group (P < 0.01), and cure rate and marked improvement rate were obviously superior to those of the drug group and the affected-channel group (P < 0.05 or P < 0.01). After treatment, the three groups all got improvements in the hemorheological indexes, of which MNEFMSA group got marked improvements in the whole blood viscosity and erythrocyte deformability rate, significantly different from the other two groups (P < 0.05). At the early stage of treatment and after treatment, the three groups all had IL-6, TXB2 and 6-keto-PGF1alpha obviously improved (P < 0.05 or P < 0.01), of which MNEFMSA group got obvious improvement in 6-keto-PGF1alpha and IL-6 ever since the early stage of the treatment (P < 0.05). CONCLUSIONS: In the treatment of acute ischemic cerebrovascular diseases, MNEFMSA can markedly raise the clinical therapeutic effects by improving the hemorheological indexes, lowering the level of IL-6, and restoring the dynamic equilibrium between TXB2 and6-keto-PGF1alpha, so as to promote the recovery of cerebral nervous function.
RCT Entities:
OBJECTIVE: To observe the therapeutic effects of midnight-noon ebb-flow method of selecting acupoints (MNEFMSA) for acute ischemic cerebrovascular diseases (AICD) and its influence on hemorrheology and on the levels of interleukin-6 (IL-6), thromboxane B2 (TXB2) and 6-keto-prostaglandin F1alpha (6-keto-PGF1alpha). METHODS: The 90 cases were randomly divided into 3 groups, each consisting of 30 cases. The drug group was treated mainly by routine medication; in addition to medication, the affected-channel group was treated by acupuncture at points along the course of the affected channel, and the MNEFMSA group was treated by MNEFMSA. RESULTS: The total effective rate of MNEFMSA group, affected-channel group and drug group was 96.67%, 90% and 73.33% respectively. The total effective rate of MNEFMSA group was obviously superior to that of the drug group (P < 0.01), and cure rate and marked improvement rate were obviously superior to those of the drug group and the affected-channel group (P < 0.05 or P < 0.01). After treatment, the three groups all got improvements in the hemorheological indexes, of which MNEFMSA group got marked improvements in the whole blood viscosity and erythrocyte deformability rate, significantly different from the other two groups (P < 0.05). At the early stage of treatment and after treatment, the three groups all had IL-6, TXB2 and 6-keto-PGF1alpha obviously improved (P < 0.05 or P < 0.01), of which MNEFMSA group got obvious improvement in 6-keto-PGF1alpha and IL-6 ever since the early stage of the treatment (P < 0.05). CONCLUSIONS: In the treatment of acute ischemic cerebrovascular diseases, MNEFMSA can markedly raise the clinical therapeutic effects by improving the hemorheological indexes, lowering the level of IL-6, and restoring the dynamic equilibrium between TXB2 and6-keto-PGF1alpha, so as to promote the recovery of cerebral nervous function.